Deutsche Bank’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Deutsche Bank’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-600	Closed	-$3.46K	–	3745
2023 Q3	$3.46K	Sell	600 -2,420	-80%	-$16.5K	﹤0.01%	3620
2023 Q2	$21.7K	Sell	3,020 -988	-25%	-$7.17K	﹤0.01%	3572
2023 Q1	$29.5K	Hold	4,008	–	–	﹤0.01%	3655
2022 Q4	$26.8K	Hold	4,008	–	–	﹤0.01%	3720
2022 Q3	$41K	Hold	4,008	–	–	﹤0.01%	3644
2022 Q2	$49K	Buy	4,008 +3,485	+666%	+$55.1K	﹤0.01%	3761
2022 Q1	$11K	Sell	523 -62	-11%	-$2.15K	﹤0.01%	4117
2021 Q4	$35K	Sell	585 -415	-42%	-$31K	﹤0.01%	4047
2021 Q3	$94K	Buy	1,000 +462	+86%	+$61.6K	﹤0.01%	3923
2021 Q2	$89K	Sell	538 -18	-3%	-$3.06K	﹤0.01%	4180
2021 Q1	$107K	Buy	+556	New	+$139K	﹤0.01%	3949

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Deutsche Bank's TLIS Position: Q4 2023 in Review

Deutsche Bank sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q4 2023, closing a stake of 600 shares — an estimated $3.46K sold.

Deutsche Bank first reported a position in TLIS in Q1 2021 and held it in 11 quarters. The position peaked at $107K in Q1 2021. 18 funds tracked by Wall St. Rank hold TLIS as of Q4 2023.

Deutsche Bank reported no remaining Talis Biomedical Corporation Common Stock position as of Q4 2023 after selling out during the quarter.
Deutsche Bank sold 600 Talis Biomedical Corporation Common Stock shares in Q4 2023, an estimated $3.46K.
Deutsche Bank first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 11 quarters.
Deutsche Bank's Talis Biomedical Corporation Common Stock position peaked at $107K in Q1 2021.
18 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q4 2023.

Based on Deutsche Bank's 13F filing for Q4 2023, filed 14 Feb 2024.